Changhai Multimodal Esophageal Cancer Cohort

NCT ID: NCT06410677

Last Updated: 2024-05-13

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 110 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2018-06-13
• Study Completion Date: 2024-10-01

Brief Summary

The burden of esophageal squamous cell carcinoma (ESCC) in China is substantial, with 85% of the cancers being in the progressive stage. The treatment for advanced ESCC are extremely limited, and immunotherapy, represented by PD-1 inhibitors, has demonstrated a promising application potential. However, the effectiveness of PD-1 inhibitors varies significantly among patients with different types of ESCC, and currently, there is no effective method to predict the response to PD-1 inhibitors. In this study, investigators aim to construct a multimodal deep learning-based model to predict the level of immune infiltration and the efficacy of immunotherapy for ESCC, integrating both pathological image features and clinical information of patients with ESCC, thereby enhancing the level of individualized and precise treatment for ESCC.

Conditions

Esophageal Squamous Cell Carcinoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

esophageal squamous cell carcinoma

DNA Sequencing, RNA Sequencing

Intervention Type: DIAGNOSTIC_TEST

High-coverage Whole-Exome Sequencing sequencing of DNA samples from ESCC was performed.

RNA expression was analyzed using the NanoString PanCancer Immuno-Oncology 360TM Panel that includes a set of more than 700 genes involved in the main biological pathways of human immunity. These experiments were performed by the Genomics platform of Institut Curie. Total RNAs were used as templates.

Interventions

DNA Sequencing, RNA Sequencing

High-coverage Whole-Exome Sequencing sequencing of DNA samples from ESCC was performed.

RNA expression was analyzed using the NanoString PanCancer Immuno-Oncology 360TM Panel that includes a set of more than 700 genes involved in the main biological pathways of human immunity. These experiments were performed by the Genomics platform of Institut Curie. Total RNAs were used as templates.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

1. Availability of Hematoxylin and Eosin (H&E) stained images, molecular data obtained through RNA sequencing (RNA-Seq, DNA-seq), and comprehensive clinical information including patient age, gender, history of alcohol consumption, history of smoking, AJCC Tumor, Node, Metastasis Stage, specific location of oesophageal cancer occurrence, and history of reflux.

2. The sample collection is restricted to cancerous tissue, encompassing both primary tumor samples and those from metastatic sites.

Exclusion Criteria

1. Patients diagnosed with adenosquamous carcinoma or presenting with a combination of other types of oesophageal cancers;

2. Cases involving combined adenocarcinoma affecting the gastroesophageal junction;

3. Individuals with high-grade tumors that have not penetrated the basement membrane, as confirmed by postoperative pathological examination;

4. Subjects in whom postoperative pathology confirms an absence of residual malignant tissue.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Wangluowei

OTHER

Sponsor Role: lead

Responsible Party

Wangluowei

M.D., PhD., Doctoral supervisor, Professor, Chief physician

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Luowei Wang

Role: STUDY_CHAIR

Changhai Hospital

Locations

Changhai hospital

Shanghai, , China

Countries

China

Other Identifiers

CMECC

Identifier Type: -

Identifier Source: org_study_id